Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: JAMA Surg. 2013 Sep;148(9):10.1001/jamasurg.2013.3044. doi: 10.1001/jamasurg.2013.3044

Figure 1.

Figure 1

a: 5 year disease specific survival for SLN+ only patients versus SLN+, NSLN+ patients. 5 year disease specific survival was significantly shorter for the SLN+ only group versus the SLN+, NSLN+ group (p=0.0002)

b: Overall survival for SLN+ only patients versus SLN+, NSLN+ patients. Median overall survival was 178 months for SLN+ only patients versus 42.2 months for SLN+, NSLN+ patients. Five year overall survival was 72.3% for SLN+ only patients versus 46.4% for SLN+, NSLN+ patients (p<0.0001)

c: Disease specific survival for SLN+ only patients versus SLN+, NSLN+ patients. Five year disease specific survival was 77.8% for the SLN+ only group and 49.5% for the SLN+, NSLN+ group (p<0.0001)